239 related articles for article (PubMed ID: 6775310)
1. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
[No Abstract] [Full Text] [Related]
2. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
Schiller B; Lysakowska E; Owczarska K
Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
[No Abstract] [Full Text] [Related]
3. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
[TBL] [Abstract][Full Text] [Related]
4. A new polyvalent pseudomonas vaccine.
Merle P; Robbel L; Hungerer KD
Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
[TBL] [Abstract][Full Text] [Related]
5. Determination of type specific IgG Pseudomonas antibodies by the ELISA test after administration of the anti Pseudomonas aeruginosa vaccine.
Meitert T; Meitert E; Pencu E; Tonciu M
Arch Roum Pathol Exp Microbiol; 1984; 43(1):53-60. PubMed ID: 6442132
[No Abstract] [Full Text] [Related]
6. Live, attenuated vaccines against Pseudomonas: observations in the experimental animal and the human.
Bellanti JA; Sordelli DO; Cerquetti MC; Wan KS; Arias G; Cereb N; Zuba D; Kulczycki L; Hooke AM
Ann Sclavo Collana Monogr; 1986; 3(1-2):247-58. PubMed ID: 3122803
[No Abstract] [Full Text] [Related]
7. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
Ding B; von Specht BU; Li Y
Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
[TBL] [Abstract][Full Text] [Related]
8. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
Jones RJ; Roe EA
Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
[TBL] [Abstract][Full Text] [Related]
9. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
10. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
Cryz SJ; Sadoff JC; Que JU
Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
[No Abstract] [Full Text] [Related]
11. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
Bukowska D; Serafińska D; Zietkiewicz W; Rudowski W; Hoffman S; Uszyński H; Molski M; Hess C; Jonecko A; Popiel D
Pol Tyg Lek; 1986 Dec; 41(49):1549-52. PubMed ID: 3108869
[No Abstract] [Full Text] [Related]
12. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
[TBL] [Abstract][Full Text] [Related]
13. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
[TBL] [Abstract][Full Text] [Related]
14. [Use of a polyvalent vaccine against Pseudomonas aeruginosa in severely burned patients].
Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
Pol Tyg Lek; 1984 Apr; 39(17):557-61. PubMed ID: 6435103
[No Abstract] [Full Text] [Related]
15. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
Daoulas-Le Bourdelles F; Berche P; Véron M
Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa infection and vaccination in the rat.
Kostiala AA
J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
[TBL] [Abstract][Full Text] [Related]
17. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
Pranter W; Staerk J; Zellner R; Zwisler O
Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
[No Abstract] [Full Text] [Related]
18. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
Ionescu A; Meitert E; Vasiliu S; Meitert T; Milicescu S; Sima F; Savulian C
Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594
[No Abstract] [Full Text] [Related]
19. Pseudomonas aeruginosa: prevention better than cure?
Mellor JA; Miler JJ
Dev Biol Stand; 1979; 43():53-9. PubMed ID: 118071
[TBL] [Abstract][Full Text] [Related]
20. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
Baumann U; Mansouri E; von Specht BU
Vaccine; 2004 Feb; 22(7):840-7. PubMed ID: 15040936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
